SEC Form 4 · accession 0001721020-26-000004
Keros Therapeutics, Inc. · KROS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alpna Seth
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 5:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001664710
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 3, 2026 | A | 7,142 | $0.00 | A | 12,392 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $10.50 | Jun 3, 2026 | A | 7,433 | A | — | Jun 2, 2036 | Common Stock | 7,433 | 7,433 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
- F2The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.